Navigation Links
AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
Date:9/10/2007

or destruction, of soft tissues in general and cardiac related surgical procedures, but to date has not cleared or approved the system for the treatment of AF. The FDA has cleared the AtriCure multifunctional bipolar Pen for the ablation of cardiac tissue and for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias, but the multifunctional bipolar Pen has not been approved for the treatment of AF.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure's products. Forward-looking statements are based on AtriCure's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure's products, AtriCure's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure's products, competition from existing and new products and procedures or AtriCure's ability to effectively react to other risks and uncertainties described from time to time in AtriCure's SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation (including the purported class action lawsuit) or other proceedings, gov
'/>"/>

SOURCE AtriCure, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2008)... associated with increased plaque , , TH...earchers has described hourly changes in a protein...n Alzheimer,s disease. , In a 2005 study, the ...d to brain cell communication in a mouse model of ... increased, so did amyloid beta. When there was re...
(Date:8/28/2008)...., the leading innovator and provider of email and...on support, compliance, and storage management, to...l Archive has won MSExchange.org,s prestigious Rea...rise Email Archive is an on-site software solution...5.5 through 2007. , Milpi...
(Date:8/28/2008)...uncil for Continuing Medical Education (ACCME) has...American Pathologists (CAP) the status of Accredit...g medical education for physicians. , ...8 -- The Accreditation Council for Continuing Medi...vision of the www.cap.org [College of American P...
(Date:8/28/2008)...e Users to Learn about Each Candidate,s Health Car... Miami, FL (PRWEB) August 28, 2008 -- Health...leader in local healthcare provider search, announ...Obama and McCain on Health Care" ( http://dec...ve voting guide for the 2008 U.S. presidential ele...
Breaking Medicine News(10 mins):Health News:Scientists Track Hourly Changes in Alzheimer's Protein 2Health News:MessageSolution Enterprise Email Archive™ Wins MSExchange.org Readers' Choice Award for Exchange Archiving 2Health News:MessageSolution Enterprise Email Archive™ Wins MSExchange.org Readers' Choice Award for Exchange Archiving 3Health News:MessageSolution Enterprise Email Archive™ Wins MSExchange.org Readers' Choice Award for Exchange Archiving 4Health News:MessageSolution Enterprise Email Archive™ Wins MSExchange.org Readers' Choice Award for Exchange Archiving 5Health News:College of American Pathologists' Education Division Receives Top Honor 2Health News:College of American Pathologists' Education Division Receives Top Honor 3Health News:HealthCare.com Launches HealthDecision '08: Obama and McCain on Health Care 2Health News:HealthCare.com Launches HealthDecision '08: Obama and McCain on Health Care 3
...a health care reform plan in January next year tha...ons of Pennsylvanians who lack coverage. Governor ...s, hospital infections etc. The plan, which was u... latest health care initiatives that have been sup...
...es of India migrate to the industrialized regions ... end up with AIDS.// Bihari migrants are estimated... usually work as taxi drivers, mechanics, security...s big cities. "I just did not think about what I ...
...hers have opined on the basis of recent studies th...not guarantee the prevention of a relapse. AC/T, ...e in preventing a relapse as compared to CEF, whic... in this regard. A new experimental chemotherapy p...
...technology will provide soft loans to pharmaceutic...gs and carry out clinical trials, the company said... is under the science and technology ministry, Ran...opment of therapeutic drugs for anti-infective and...
Other Medicine News:Health News:Poverty Fuels HIV In Poor Indian States 2
(Date:8/28/2008)... --, - Results Further Support the Clinical Profi...nt to Improve the Survival of Patients,With Hormon...OSE: ALGETA), the Norwegian cancer therapeutics co...of its BC1-03 Phase II pain,palliation study was m...haradin in patients with painful bone metastases c...
(Date:8/27/2008)...FirstCall/ --, - Oralair(R) Grasses 300IR Highly ...dy Conducted in an Allergen Challenge Chamber, St...lts of a new study,conducted in an Allergen Challe...es included 86 adult patients exposed to,grass pol...1 week, 1 month,2 and 4 months without a titratio...
(Date:8/26/2008)...Semafore Pharmaceuticals Inc.,announced data prese...eted,Therapies in Cancer in Washington, D.C., show...-targeted PI3 kinase (PI3K) inhibitor SF1126, by,b...t of a very powerful pathway, the PI3/AKT /mTOR pa...cancer. Studies have shown that by,inhibiting this...
(Date:8/26/2008)...e-FirstCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today...ta,from the CUSTOM II trial was published in the m...oIntervention. The lead author of the article was,...Center Utrecht, Utrecht,The Netherlands on behalf...ites across Europe., The one-year CUSTOM II trial...
Breaking Medicine Technology:Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 2Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 3Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 4Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 2SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Elbow Injuries on Rise Among Young Athletes 23884 1Elbow Injuries on Rise Among Young Athletes 23884 2Elbow Injuries on Rise Among Young Athletes 23884 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 1Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 2Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 4Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 5Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 6Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 7Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 8Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 9Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 10Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 11FDA Updates Label for AVANDIA 28R 29 to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 2623 1FDA Updates Label for AVANDIA 28R 29 to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 2623 2FDA Updates Label for AVANDIA 28R 29 to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 2623 3Eularis Analyzes Most Effective Generics Defense Strategies With New Pharmaceutical Industry Report 23877 1Eularis Analyzes Most Effective Generics Defense Strategies With New Pharmaceutical Industry Report 23877 2Eularis Analyzes Most Effective Generics Defense Strategies With New Pharmaceutical Industry Report 23877 3
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches.
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches.
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches.
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches.
Medicine Products: